Use of Medications to Lower Urine Protein Level in Patients with Diabetic Kidney Disease

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2010 Jun 10

PMID 20532702

Authors

Robert C Stanton

Affiliations

Soon will be listed here.

References

Farquharson C, Struthers A . Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000; 101(6):594-7. DOI: 10.1161/01.cir.101.6.594. View

Tian W, Braunstein L, Pang J, Stuhlmeier K, Xi Q, Tian X . Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem. 1998; 273(17):10609-17. DOI: 10.1074/jbc.273.17.10609. View

Chatzikyrkou C, Menne J, Haller H . How to achieve renal protection in the light of ONTARGET?. J Hypertens Suppl. 2009; 27(2):S15-7. DOI: 10.1097/01.hjh.0000354514.59827.04. View

Slagman M, Navis G, Laverman G . Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Curr Opin Nephrol Hypertens. 2010; 19(2):140-52. DOI: 10.1097/MNH.0b013e3283361887. View

Zhang Z, Apse K, Pang J, Stanton R . High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem. 2000; 275(51):40042-7. DOI: 10.1074/jbc.M007505200. View

McMurray J, Ostergren J, Swedberg K, Granger C, Held P, Michelson E . Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362(9386):767-71. DOI: 10.1016/S0140-6736(03)14283-3. View

Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London G . Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1998; 10(12 Pt 1):1326-34. DOI: 10.1016/s0895-7061(97)00301-4. View

Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T . Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009; 361(1):40-51. PMC: 2978030. DOI: 10.1056/NEJMoa0808400. View

Duprez D, De Buyzere M, Rietzschel E, Taes Y, Clement D, Morgan D . Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998; 19(9):1371-6. DOI: 10.1053/euhj.1998.1099. View

10.

Xu Y, Osborne B, Stanton R . Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol. 2005; 289(5):F1040-7. DOI: 10.1152/ajprenal.00076.2005. View

11.

Bakris G, Weir M, Secic M, Campbell B, Weis-McNulty A . Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004; 65(6):1991-2002. DOI: 10.1111/j.1523-1755.2004.00620.x. View

12.

Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15):1547-59. DOI: 10.1056/NEJMoa0801317. View

13.

Tian W, Braunstein L, Apse K, Pang J, Rose M, Tian X . Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol. 1999; 276(5):C1121-31. DOI: 10.1152/ajpcell.1999.276.5.C1121. View

14.

Schwab S, CHRISTENSEN R, Dougherty K, KLAHR S . Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med. 1987; 147(5):943-4. View

15.

Gerstein H, Mann J, Yi Q, Zinman B, Dinneen S, Hoogwerf B . Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4):421-6. DOI: 10.1001/jama.286.4.421. View

16.

McCormick B, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G . The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis. 2008; 52(3):454-63. DOI: 10.1053/j.ajkd.2008.01.025. View

17.

Ninomiya T, Perkovic V, de Galan B, Zoungas S, Pillai A, Jardine M . Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009; 20(8):1813-21. PMC: 2723977. DOI: 10.1681/ASN.2008121270. View

18.

Leopold J, Dam A, Maron B, Scribner A, Liao R, Handy D . Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007; 13(2):189-97. PMC: 3648863. DOI: 10.1038/nm1545. View

19.

Krum H, Carson P, Farsang C, Maggioni A, Glazer R, Aknay N . Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004; 6(7):937-45. DOI: 10.1016/j.ejheart.2004.09.005. View

20.

Parving H, Persson F, Lewis J, Lewis E, Hollenberg N . Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358(23):2433-46. DOI: 10.1056/NEJMoa0708379. View